Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JOMZC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
38354417 T-DL3
|
|||||
| Synonyms |
T-DL3
Click to Show/Hide
|
|||||
| Organization |
ADC Therapeutic Development, Zymeworks Inc., Vancouver, British Columbia, Canada.
|
|||||
| Drug Status |
Investigative
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
FD2
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
MT-GGFG-AM
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
ADC-specific functional property(2027 Update)
Circulating Stability
| Incubation Time | 7days | Release | 0% | Reference |
[1]
|
|---|---|---|---|---|---|
| Incubation Medium | mouse plasma | ||||
| Description |
The stability of the nine ADCs was evaluated in mouse plasma for 7 days followed by immunoprecipitation-mass spectrometry analysis.
|
||||
Bystander Killing Effect
| Bystander Killing Effect | Description | Reference |
|---|---|---|
| yes |
HER2-negative MDA-MB-468 cells were grown in either monoculture or in coculture with the HER2-high SK-BR-3 cells then treated with either 0.1 or 1 nmol/L of ADC: At 1 nmol/L concentration, ADC T-DL3 showed rather lower bystander killing.
Click to Show/Hide
|
[1]
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.007 nM | High HER2 expression (HER2 +++) | ||
| Method Description |
A total of 30,000 SK-BR-3 (HER2-high) cells were seeded either as monocultures or cocultures in TC-treated 48-well microtiter plates (Greiner Bio-One, catalog no. 667180) and treated with 1.0 or 0.1 nmol/L ADCs diluted in growth medium.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 30 nM | Negative HER2 expression (HER2-) | ||
| Method Description |
A total of 10,000 MDA-MB-468 (HER2-negative) cells were seeded either as monocultures or cocultures in TC-treated 48-well microtiter plates (Greiner Bio-One, catalog no. 667180) and treated with 1.0 or 0.1 nmol/L ADCs diluted in growth medium.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
References